Skip to content

Study · Non-randomized trial · n = 12 · 2026

2 results

Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans.

Galbiati F, Plessow F, Plummer L, Campbell MB, Nazarloo S, Carter CS, Davis JM, Miller KK, Carroll RS, Kaiser UB, Seminara SB, Aulinas A, Lawson EA

Journal of neuroendocrinology22 Nov 2025Cited by 1 (Europe PMC)

PMID41273106 (opens in a new tab)PMCIDPMC12797869 (opens in a new tab)DOI10.1111/jne.70114 (opens in a new tab)PepBankPUB-41273106
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy adults, an intravenous KP bolus did not change serum AVP levels.

    In plain wordsIn healthy adults, kisspeptin given into a vein did not change levels of the hormone vasopressin.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeSerum AVP response to KP bolus
    Study

    n = 12

    Comparator
    Pre-KP baseline
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    0.24 nmol/kg · intravenous · bolusAs given in this study (human).

    Source sentences

    Summary
    did not change in response to KP.
    3 context sentences
    Summary · context
    Serum AVP was measured pre- and 10, 20, 40, and 60 min post-KP.
    Summary · context
    Twelve healthy adults (50% female) received an IV KP bolus.
    Summary · context
    Our study does not support IV KP bolus of 0.24 nmol/kg as a provocative test for AVP-D.
  2. 02HumanNon-randomized trialOther

    In healthy adults, AVP levels were higher in males than in females at all time points.

    In plain wordsIn healthy adults, vasopressin levels were higher in men than in women at every time point.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableSex difference in AVP level
    Study

    n = 12

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    0.24 nmol/kg · intravenous · bolusAs given in this study (human).

    Source sentences

    Summary
    AVP levels were higher in males at all time points (p = .028)
    2 context sentences
    Summary · context
    Twelve healthy adults (50% female) received an IV KP bolus.
    Summary · context
    Our study does not support IV KP bolus of 0.24 nmol/kg as a provocative test for AVP-D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00914823

Kisspeptin Administration in the Adult

Massachusetts General Hospitaln = 25623 Jun 2009 to 22 Oct 2021

Hypogonadotropic Hypogonadism · Kallmann Syndrome · GnRH Deficiency · PCOS · Polycystic Ovarian Syndrome · Hyperprolactinemia

Trial pageClinicalTrials.govUpdated 31 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.